Loading
Life sciences · Journal article
International Journal of Molecular Sciences · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity-driven hyperleptinemia is a key driver of breast cancer (BC) aggressiveness; nevertheless, strategies to counteract leptin-mediated tumor progression remain limited. Curcumin, a natural polyphenol with established anti-obesity, anti-inflammatory, and anticancer properties, has emerged as a promising metabolic and tumor-modulating biomolecule, although its effects on leptin-induced oncogenic signaling remain unclear. This study evaluated Curcumin as an adjuvant nutraceutical against leptin-induced oncogenesis in MCF-7 and MDA-MB-231 cells. Cells were exposed to obesity-mimicking leptin levels alone or with non-toxic Curcumin doses. MTT, clonogenic, wound-healing, and 3D spheroid dissemination assays were used to assess phenotypic changes, while network pharmacology and molecular docking explored underlying mechanisms. Curcumin significantly inhibited leptin-induced proliferation (8–17%), colony formation (60–90%), migration (20–45%), and 3D spheroid dissemination (20%) in both BC cell lines. Network pharmacology identified shared hub proteins, including AKT1, RHOA, MAP2K1, and MAPK14, linking Curcumin targets with leptin-driven BC signatures, and molecular docking supported direct interactions of Curcumin with these proteins. These findings suggest that Curcumin counteracts hyperleptinemia-induced tumor progression by targeting the PI3K/AKT, MAPK/ERK, and RHOA/ROCK pathways. This integrated in vitro and in silico study supports Curcumin as a promising adjuvant nutraceutical for obesity-associated BC, although experimental pathway validation is still required.